Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifampin

FDA-approved product (capsule, oral), marketed as Rifadin, Rifampin, Rimactane.

Registered studies
50+
Lab records
242
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Rifampin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Pulmonary tuberculosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
FDA pharmacologic class
Rifamycin Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB02; FDA class Rifamycin Antibacterial

Repurposing investigation

Rifampin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli88.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae74.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis96.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 3 of 3 lab records
  • E. coli: measured active in 4 of 4 lab records
  • K. pneumoniae: measured active in 16 of 19 lab records
  • M. tuberculosis: measured active in 207 of 216 lab records
Open Rifampin in ChEMBL Registered studies below
Show the latest 150 of 242 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifampin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effects of Rifampin on the Pharmacokinetics of Ataluren

    NCT02409004 · start 2015-02

    Registered record
    Registry ID
    NCT02409004
    Conditions
    Healthy
    Interventions
    Ataluren; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-02
    Completion
    2015-03
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAtaluren; Rifampin
    PhasePhase 1
    Registry statusCompleted

  • A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

    NCT01954043 · start 2013-12-20

    Registered record
    Registry ID
    NCT01954043
    Conditions
    Cancer
    Interventions
    Dabrafenib 150 mg twice a day (BID); Rabeprazole 40 mg once daily (OD); Rifampin 600 mg OD
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-12-20
    Completion
    2016-02-29
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionDabrafenib 150 mg twice a day (BID); Rabeprazole 40 mg once daily (OD); Rifampin 600 mg OD
    PhasePhase 1
    Registry statusCompleted

  • A Study of Baricitinib and Rifampicin in Healthy Participants

    NCT01910311 · start 2013-08

    Registered record
    Registry ID
    NCT01910311
    Conditions
    Healthy Volunteers
    Interventions
    Baricitinib; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-08
    Completion
    2013-10
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionBaricitinib; Rifampicin
    PhasePhase 1
    Registry statusCompleted

  • Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

    NCT01844583 · start 2013-06-25

    Registered record
    Registry ID
    NCT01844583
    Conditions
    Solid Tumors; Lymphoma
    Interventions
    Alisertib; Esomeprazole; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-06-25
    Completion
    2016-09-06
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors; Lymphoma
    InterventionAlisertib; Esomeprazole; Rifampin
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects

    NCT01587469 · start 2012-05

    Registered record
    Registry ID
    NCT01587469
    Conditions
    Tuberculosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-05
    Completion
    2014-02-21
    Enrolment
    992

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

    NCT01454076 · start 2011-11-10

    Registered record
    Registry ID
    NCT01454076
    Conditions
    Nonhematologic Malignancies; Lymphoma
    Interventions
    Ixazomib 2.5 mg; Ixazomib 4 mg Capsule A; Ixazomib 4 mg Capsule B; Ketoconazole; Rifampin; Clarithromycin; Ixazomib 4 mg Capsule B
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-11-10
    Completion
    2016-06-16
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNonhematologic Malignancies; Lymphoma
    InterventionIxazomib 2.5 mg; Ixazomib 4 mg Capsule A; Ixazomib 4 mg Capsule B; Ketoconazole +3 more
    PhasePhase 1
    Registry statusCompleted

  • A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

    NCT01591850 · start 2011-09

    Registered record
    Registry ID
    NCT01591850
    Conditions
    Healthy Volunteer
    Interventions
    RO5093151; atazanavir; ketoconazole; rifampicin; ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-09
    Completion
    2011-11
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionRO5093151; atazanavir; ketoconazole; rifampicin +1 more
    PhasePhase 1
    Registry statusCompleted

  • PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay

    NCT01225640 · start 2011-08

    Registered record
    Registry ID
    NCT01225640
    Conditions
    Tuberculosis
    Interventions
    PNU-100480; PNU-100480; RHZE
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-08
    Completion
    2011-12
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionPNU-100480; PNU-100480; RHZE
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis

    NCT00760149 · start 2010-07

    Registered record
    Registry ID
    NCT00760149
    Conditions
    Tuberculosis
    Interventions
    Rifampicin in higher doses
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-07
    Completion
    2013-09
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifampicin in higher doses
    PhasePhase 2
    Registry statusCompleted

  • Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers

    NCT01147055 · start 2010-07

    Registered record
    Registry ID
    NCT01147055
    Conditions
    Healthy
    Interventions
    crizotinib; rifampin; crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-07
    Completion
    2010-10
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventioncrizotinib; rifampin; crizotinib
    PhasePhase 1
    Registry statusCompleted

  • Colistin Plus Rifampicin in MDR P. Aeruginosa and A. Baumanii

    NCT01297855 · start 2010-06

    Registered record
    Registry ID
    NCT01297855
    Conditions
    Drug Safety
    Interventions
    Colistin; Colistin plus Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2010-06
    Completion
    2012-08
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Safety
    InterventionColistin; Colistin plus Rifampicin
    PhasePhase 3
    Registry statusUnknown

  • Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa

    NCT01063270 · start 2010-02

    Registered record
    Registry ID
    NCT01063270
    Conditions
    Hidradenitis Suppurativa
    Interventions
    Clindamycin & Rifampin; Clindamycin + Rifampin along with NdYag Laser treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-02
    Completion
    2013-12
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHidradenitis Suppurativa
    InterventionClindamycin & Rifampin; Clindamycin + Rifampin along with NdYag Laser treatment
    PhaseNot applicable
    Registry statusCompleted

  • Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib

    NCT00864487 · start 2009-04

    Registered record
    Registry ID
    NCT00864487
    Conditions
    Healthy Subjects
    Interventions
    Neratinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-04
    Completion
    2009-05
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionNeratinib
    PhasePhase 1
    Registry statusCompleted

  • Influence of Drug-drug Interactions on the Pharmacokinetics (PK) of Voriconazole

    NCT01080651 · start 2008-12

    Registered record
    Registry ID
    NCT01080651
    Conditions
    Invasive Aspergillosis
    Interventions
    Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-12
    Completion
    2009-03
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Aspergillosis
    InterventionVoriconazole
    PhasePhase 1
    Registry statusCompleted

  • Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis

    NCT00617643 · start 2008-05

    Registered record
    Registry ID
    NCT00617643
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Nevirapine without dose escalation; Nevirapine initiation with dose escalation
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-05
    Completion
    2010-12
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionNevirapine without dose escalation; Nevirapine initiation with dose escalation
    PhasePhase 4
    Registry statusCompleted